This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Woods, W. G. Articles by Lange, B. J. Search for Related Content PubMed PubMed Citation Articles by Woods, W. G. Articles by Lange, B. J.

Prospective Study of 90 Children Requiring Treatment for Juvenile Myelomonocytic Leukemia or Myelodysplastic Syndrome: A Report From the Children’s Cancer Group

From the AFLAC Cancer Center, Emory University/Children’s Healthcare, Atlanta, GA; Izaak W. Killam Hospital for Children, Halifax, Nova Scotia; University of Southern California Keck School of Medicine, Los Angeles, CA; Roger Maris Cancer Center, Fargo, ND; National Cancer Institute, Bethesda, MD; Fred Hutchinson Cancer Research Center, Seattle, WA; Children’s Hospital of Pittsburgh, Pittsburgh, PA; University of North Carolina, Chapel Hill, NC; and Children’s Hospital of Philadelphia, Philadelphia, PA.

Address reprint requests to William G. Woods, MD, Children’s Cancer Group, PO Box 60012, Arcadia, CA 91066-6012; email: william.woods{at}choa.org

PURPOSE: We report the first large prospective study of children with myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) treated in a uniform fashion on Children’s Cancer Group protocol 2891.

PATIENTS AND METHODS: Ninety children with JMML, various forms of MDS, or acute myeloid leukemia (AML) with antecedent MDS were treated with a five-drug induction regimen (standard or intensive timing). Patients achieving remission were allocated to allogeneic bone marrow transplantation (BMT) if a matched family donor was available. All other patients were randomized between autologous BMT and aggressive nonmyeloablative chemotherapy. Results were compared with patients with de novo AML.

RESULTS: Patients with JMML and refractory anemia (RA) or RA-excess blasts (RAEB) exhibited high induction failure rates and overall remission of 58% and 48%, respectively. Remission rates for patients with RAEB in transformation (RAEB-T) (69%) or antecedent MDS (81%) were similar to de novo AML (77%). Actuarial survival rates at 6 years were as follows: JMML, 31% ± 26%; RA and RAEB, 29% ± 16%; RAEB-T, 30% ± 18%; antecedent MDS, 50% ± 25%; and de novo AML, 45% ± 3%. For patients achieving remission, long-term survivors were found in those receiving either allogeneic BMT or chemotherapy. The presence of monosomy 7 had no additional adverse effect on MDS and JMML.

CONCLUSION: Childhood subtypes of MDS and JMML represent distinct entities with distinct clinical outcomes. Children with a history of MDS who present with AML do well with AML-type therapy. Patients with RA or RAEB respond poorly to AML induction therapy. The optimum treatment for JMML remains unknown.

This article has been cited by other articles:

				S. J. Lee, S. Joffe, A. S. Artz, R. E. Champlin, S. M. Davies, M. Jagasia, N. A. Kernan, F. R. Loberiza Jr, R. J. Soiffer, and M. Eapen Individual Physician Practice Variation in Hematopoietic Cell Transplantation J. Clin. Oncol., May 1, 2008; 26(13): 2162 - 2170. [Abstract] [Full Text] [PDF]

				B. J. Lange, F. O. Smith, J. Feusner, D. R. Barnard, P. Dinndorf, S. Feig, N. A. Heerema, C. Arndt, R. J. Arceci, N. Seibel, et al. Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group Blood, February 1, 2008; 111(3): 1044 - 1053. [Abstract] [Full Text] [PDF]

				S. Archambeault, N. J. Flores, A. Yoshimi, C. P. Kratz, M. Reising, A. Fischer, P. Noellke, F. Locatelli, P. Sedlacek, C. Flotho, et al. Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia Blood, February 1, 2008; 111(3): 1124 - 1127. [Abstract] [Full Text] [PDF]

				C. Flotho, C. P. Kratz, and C. M. Niemeyer How a rare pediatric neoplasia can give important insights into biological concepts: a perspective on juvenile myelomonocytic leukemia Haematologica, November 1, 2007; 92(11): 1441 - 1446. [Full Text] [PDF]

				H. Hasle, T. A. Alonzo, A. Auvrignon, C. Behar, M. Chang, U. Creutzig, A. Fischer, E. Forestier, A. Fynn, O. A. Haas, et al. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study Blood, June 1, 2007; 109(11): 4641 - 4647. [Abstract] [Full Text] [PDF]

				F. Locatelli, P. Nollke, M. Zecca, E. Korthof, E. Lanino, C. Peters, A. Pession, H. Kabisch, C. Uderzo, C. S. Bonfim, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial Blood, January 1, 2005; 105(1): 410 - 419. [Abstract] [Full Text] [PDF]

				C.-H. Pui, M. Schrappe, R. C. Ribeiro, and C. M. Niemeyer Childhood and Adolescent Lymphoid and Myeloid Leukemia Hematology, January 1, 2004; 2004(1): 118 - 145. [Abstract] [Full Text] [PDF]